Table 1. .
Description of the Study Population at Antiretroviral Therapy Initiation
| N = 717 | Initial ART Backbone | P | |||
|---|---|---|---|---|---|
| NRTI + NNRTI (n = 211) | NRTI + PI (n = 419) | NRTI + INSTI (n = 87) | |||
| Male/female (% male) | 527/190 (73.5) | 171/40 (81.0) | 293/126 (69.9) | 63/24 (72.4) | .01 |
| Age (n = 716), y | 39 (32–46) | 39 (32–47) | 38 (32–45) | 42 (34–51) | .009 |
| Hospital | .005 | ||||
| La Pitié-Salpétrière | 519 (72.4) | 160 (75.8) | 286 (68.3) | 73 (83.9) | |
| Saint-Antoine | 198 (27.6) | 51 (24.2) | 133 (31.7) | 14 (16.1) | |
| Time since first positive HIV serology, y | 0.2 (0.1–2.4) | 0.5 (0.1–2.5) | 0.2 (0.1–2.3) | 0.1 (0.1–2.9) | .2 |
| AIDS-defining illness | 103 (14.4) | 16 (7.8) | 75 (17.9) | 12 (13.8) | .002 |
| CD4+ T-cell count (n = 666), /mm3 | 306 (178–441) | 366 (268–467) | 275 (137–408) | 322 (210–408) | <.001 |
| Nadir CD4+ T-cell count, mm3 | 275 (157–374) | 328 (242–410) | 238 (110–349) | 278 (168–360) | <.001 |
| CD8+ T-cell count (n = 643), /mm3 | 780 (538–1141) | 822 (586–1241) | 764 (497–1115) | 780 (564–1167) | .10 |
| CD4:CD8 ratio (n = 643) | 0.35 (0.21–0.57) | 0.41 (0.24–0.63) | 0.31 (0.17–0.51) | 0.35 (0.21–0.57) | <.001 |
| HIV-RNA viral load, log10 copies/mL | 4.84 (4.36–5.24) | 4.68 (4.17–5.08) | 4.90 (4.41–5.33) | 4.84 (4.49–5.29) | <.001 |
| HIV-RNA viral load >105 copies/mL | 292 (40.7) | 66 (31.3) | 187 (44.6) | 39 (44.8) | .004 |
| HIV subtype (n = 105) | .7 | ||||
| B | 43 (41.0) | 12 (48.0) | 25 (37.3) | 6 (46.2) | |
| CRF02_AG | 34 (32.4) | 6 (24.0) | 25 (37.3) | 3 (23.1) | |
| Other | 28 (26.7) | 7 (28.0) | 17 (25.4) | 4 (30.8) | |
| No. of antiretroviral agents | 3 (3–3) | 3 (3–3) | 3 (3–3) | 3 (3–3) | .6 |
| Positive HCV RNA (n = 291) | 18 (6.2) | 4 (5.5) | 7 (3.9) | 7 (18.9) | .002 |
| HCV RNA viral load, log10 IU/mLa | 6.20 (5.70–6.55) | 6.20 (5.52–6.56) | 6.55 (5.88–6.71) | 6.15 (5.63–6.39) | .5 |
| Positive HBsAg serology (n = 705) | 23 (3.3) | 5 (2.4) | 18 (4.3) | 0 (0) | .09 |
| Switching ART regimen during follow-up | 425 (59.3) | 92 (43.6) | 284 (67.8) | 49 (56.3) | <.001 |
| No. of switches during follow-upb | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | .8 |
All statistics are No. (%), except for continuous variables, where data are reported as median (interquartile range).
Abbreviations: ART, antiretroviral therapy; HCV, hepatitis C virus; NNRTI, non–nucleoside/nucleotide reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor.
aOnly among patients with positive HCV RNA viral loads.
bOnly among patients switching ART regimens at least once.